« Back to news

Ventus Therapeutics to Present at the Canadian Chemistry Conference and Exhibition

Oral Presentation on June 8th, 2023 at 9:40 AM PT: “Why Water? Introducing ReSOLVETM: A Dynamic Solvation Tool for Prospective Drug Discovery”

WALTHAM, Mass. & MONTREAL — June 1, 2023 — (BUSINESS WIRE) — Ventus Therapeutics, a biopharmaceutical company utilizing structural biology and a proprietary computational chemistry platform to identify and develop differentiated small molecule therapeutics across a broad range of diseases, announced today that the company’s Head of Platform Technologies, Jason Burch, Ph.D., will give an oral presentation on ReSOLVETM, Ventus’ proprietary drug discovery platform, at the Canadian Chemistry Conference and Exhibition (CSC) 2023, being held on June 4-8, 2023 in Vancouver, British Columbia.

Details of oral presentation:

TitleWhy water? Introducing ReSOLVETM: A Dynamic Solvation Tool for Prospective Drug Discovery
Abstract ID506
Date / TimeJune 8, 2023 at 9:40-10:00 AM PT (12:40-1:00 PM ET)
Session(BM, OR) Modern Approaches for Drug Discovery – From New Reactions to Medicinal Chemistry (Thursday AM1)
LocationWest Meeting Room 202
PresenterJason Burch, Ph.D., Vice President, Head of Platform Technologies, Ventus Therapeutics

The ReSOLVETM platform, which integrates cutting-edge structural biology, molecular dynamics, and water structure analysis to advance drug discovery, provides Ventus with a differentiated capability to analyze and visualize protein dynamics at a level of detail not available to others, leading to the identification of promising binding pockets that adopt many transient conformations. With these unique insights, Ventus can create a dynamic blueprint of the binding pocket, referred to as the hydrocophoreTM, which provides specific guidance on the pocket’s size, shape, and polarity. Ventus can then use the hydrocophoreTM to screen billions of compounds with greater accuracy than conventional drug discovery approaches in order to identify and advance novel differentiated small molecules in a much more time- and cost-efficient manner.

For more information about Ventus’ ReSOLVETM platform and pipeline programs, visit: www.ventustx.com.

About Ventus Therapeutics
Ventus Therapeutics is a biopharmaceutical company deploying leading-edge structural biology and computational chemistry tools to create novel small molecule medicines for challenging targets, with an initial focus on immunology, inflammation, and neurology. The Company’s proprietary drug discovery platform, ReSOLVETM, gives it the ability to discover and develop medicines through unique insights into protein targets and to create dynamic blueprints that can guide the development of differentiated therapies at a fast pace. Ventus’ first target screen was conducted in 2020, which led to the nomination of three development candidates in 2022, including: VENT-03, a potential first-in-class cGAS inhibitor; VENT-02, a brain-penetrant NLRP3 inhibitor; and VENT-01, a peripherally restricted NLRP3 inhibitor. These programs exemplify Ventus’ unique discovery capabilities and focus on first- and best-in-class programs for multi-indication immunology targets with franchise potential. For more information, please visit www.ventustx.com and engage with Ventus on LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements about future expectations, plans, and prospects, including, but not limited to, statements related to the anticipated benefits of Ventus’ business strategy, pipeline programs, drug discovery platform, and financial position. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements due to the risks and uncertainties inherent in Ventus’ business, which include, without limitation, the timing, progress, and results of preclinical and clinical studies involving its development programs; the results of its earlier studies not being predictive of future results; its ability to enhance the ReSOLVETM platform; its ability to continue to obtain funding for its operations and to implement its business strategy; the impact of the COVID-19 pandemic on its business; anticipated developments related to its competitors and its industry; the performance of third-party service providers, including suppliers, manufacturers, and CROs; and its ability to obtain, maintain, and protect its intellectual property. Any forward-looking statements contained in this press release speak only as of the date hereof, and Ventus undertakes no duty or obligation to update any forward-looking statements as a result of new information, future events, or otherwise.

Media Contact
Alexis Feinberg
ICR Westwicke